J&J/Alza’s Ionsys To Launch In 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
The fentanyl treatment’s availability waits on completion of a risk management plan despite FDA approval.
You may also be interested in...
J&J Advances Pipeline With Yondelis, Carisbamate Filings
Johnson & Johnson progressed its pipeline with the filing of two novel drugs late in 2008: trabectedin (marketed outside the U.S. as Yondelis) for the treatment of relapsed ovarian cancer, and carisbamate for the adjunctive treatment of partial onset seizures
J&J Advances Pipeline With Yondelis, Carisbamate Filings
Johnson & Johnson progressed its pipeline with the filing of two novel drugs late in 2008: trabectedin (marketed outside the U.S. as Yondelis) for the treatment of relapsed ovarian cancer, and carisbamate for the adjunctive treatment of partial onset seizures
J&J Advances Pipeline With Yondelis, Carisbamate Filings
Company is on track to achieve goal of filing seven to 10 new products from the beginning of 2008 through end of 2010, CEO Weldon says.